Fracture risk is increased in patients with GH deficiency or untreated prolactinomas – a case‐control study
- 1 February 2002
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 56 (2) , 159-167
Abstract
Objective The pituitary secretes many hormones of significance to bone turnover and thus skeletal integrity. The aim of this study was to examine fracture risk in patients with pituitary disorders with special reference to GH deficiency and hyperprolactinaemia. design Case‐control study. measurements Fracture occurrence. patients A self‐administered questionnaire was issued to 537 consecutive patients with pituitary disorders excluding Cushing’s disease. A total of 426 (79%) returned the questionnaire and 422 of these could be analysed. Each respondent was compared to three age‐ and gender‐matched control respondents to the same questionnaire drawn randomly from the background population. results The patients had a mean age of 51·4 ± 14·8 years. One hundred and eight patients had acromegaly, 86 had prolactinomas, 136 had non‐functioning pituitary adenomas (NFPA), 23 had craniopharyngiomas, and 73 had other types of pituitary disorders. For the total group the fracture risk was not elevated either before or after confirmed diagnosis compared to controls. However, among the patients with prolactinomas, the fracture risk was significantly increased before (relative risk, RR = 1·6, 95% CI: 1·1–2·3) but not after diagnosis. In patients with NFPA, fracture risk was borderline significantly elevated following diagnosis (RR = 1·6, 95% CI: 1·0–2·6). Patients with subnormal stimulated peak GH values suggestive of GH deficiency had a significantly higher risk of fractures after diagnosis than patients who had normal stimulated peak GH values (odds ratio, OR = 4·90, 95% CI: 1·10–21·88). conclusions Untreated prolactinomas were associated with a significant increase in fracture risk. Growth hormone deficiency was also associated with a higher fracture risk.Keywords
This publication has 35 references indexed in Scilit:
- The Influence of Growth Hormone Deficiency, Growth Hormone Replacement Therapy, and Other Aspects of Hypopituitarism on Fracture Rate and Bone Mineral DensityJournal of Bone and Mineral Research, 2001
- Fractures in Patients with Primary Idiopathic HypothyroidismThyroid®, 2000
- Growth Hormone Treatment in Adults with Adult-Onset Growth Hormone Deficiency Increases Iliac Crest Trabecular Bone Turnover: A 1-Year, Double-Blind, Randomized, Placebo-Controlled StudyJournal of Bone and Mineral Research, 2000
- Peak Bone Mass in Young Healthy Men Is Correlated with the Magnitude of Endogenous Growth Hormone SecretionThe Journal of Clinical Endocrinology & Metabolism, 1998
- Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic MalesThe Journal of Clinical Endocrinology & Metabolism, 1998
- Consensus Guidelines for the Diagnosis and Treatment of Adults with Growth Hormone Deficiency: Summary Statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone DeficiencyThe Journal of Clinical Endocrinology & Metabolism, 1998
- Elderly Patients with Adult-Onset Growth Hormone Deficiency Are Not OsteopenicThe Journal of Clinical Endocrinology & Metabolism, 1997
- Bone mineral density and parameters of bone metabolism in patients with acromegalyJournal of Bone and Mineral Research, 1993
- Progressive trabecular osteopenia in women with hyperprolactinemic amenorrheaThe Journal of Clinical Endocrinology & Metabolism, 1992
- Erhöhte Prävalenz von Osteoporose und Arteriosklerose bei konventionell substituierter Hypophysenvorderlappeninsuffizienz: Bedarf einer zusätzlichen Wachstumshormonsubstitution?Journal of Molecular Medicine, 1991